pf-05221304
Small moleculeexperimental
Clinical trial activity
11 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Aug 12, 2016 (NCT02871037)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pf-05221304
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04399538 | Phase 2 | Aug 1, 2020 | Pfizer |
| NCT04395950 | Phase 1 | Jul 31, 2020 | Columbia University, Pfizer |
| NCT04321031 | Phase 2 | Jun 15, 2020 | Pfizer |
| NCT03871439 | Phase 1 | Mar 13, 2019 | Pfizer |
| NCT03776175 | Phase 2 | Jan 4, 2019 | Pfizer |
| NCT03597217 | Phase 1 | Aug 27, 2018 | Pfizer |
| NCT03534648 | Phase 1 | Apr 19, 2018 | Pfizer |
| NCT03448172 | Phase 1 | Apr 18, 2018 | Pfizer |
| NCT03309202 | Phase 1 | Dec 19, 2017 | Pfizer |
| NCT03248882 | Phase 2 | Aug 22, 2017 | Pfizer |
| NCT02871037 | Phase 1 | Aug 12, 2016 | Pfizer |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 11 | 10 | 2 | 2016 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1